ClinicalTrials.gg
CompletedNCT02181322Updated Jul 8, 2014

Study to Assess the Effect of Food on the Pharmacokinetics of Meloxicam After Single Administration and to Investigate Dose-proportionality Over a Dosage Range

A Phase 1 interventional study of Meloxicam - low dose and Meloxicam - medium dose in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 21 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
21 Years to 50 Years
Sex
All
01

Study summary

Study to assess the effect of food on the pharmacokinetics of meloxicam after a single p.o. administration of 22.5 mg meloxicam oral suspension and to investigate dose-proportionality over a dosage range of 7.5 mg to 22.5 mg

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subjects as determined by results of screening
  • Age range from 21 to 50 years
  • Broca-Index +- 20%
  • In accordance with Good Clinical Practice (GCP) and the local legislation all volunteers will have given their written prior to admission to the study

Exclusion criteria

Exclusion Criteria:

  • Any finding of the medical examination (including blood pressure, pulse rate and ) deviating from normal and of clinical relevance
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of the gastro-intestinal tract (except appendectomy)
  • Disease of the central nervous system (such a epilepsy) or psychiatric disorders or neurological disorders
  • History of orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Intake of drugs with a long half-life (> 24 hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study
  • Use of any drugs which might influence the results of the trial (\<= one week prior to administration or during the trial)
  • Participation in another trial with an drug (\<= two months prior to administration or during the trial)
  • Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
  • Inability to refrain from smoking on trial days
  • Alcohol abuse (> 60 g/day)
  • Drug abuse
  • Blood donation (>= 100 mL within four weeks prior to administration or during the trial
  • Excessive physical activities (within the last week before study)
  • Anl laboratory value outside the reference range of clinical relevance
  • History of haemorrhagic diatheses
  • History of gastrointestinal ulcer, perforation or bleeding
  • History of bronchial asthma

For female subjects:

  • Pregnancy
  • Positive pregnancy test
  • No adequate e.g sterilisation, intrauterine pessary, oral contraceptives
  • Inability to maintain this adequate contraception during the whole study period
  • Lactating
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Meloxicam - low dose, fasted

    Drug: Meloxicam - low dose

  • Experimental
    Meloxicam - medium dose, fasted

    Drug: Meloxicam - medium dose

  • Experimental
    Meloxicam - high dose, fasted

    Drug: Meloxicam - high dose

  • Experimental
    Meloxicam - high dose, fed

    Drug: Meloxicam - high dose

Interventions

  • DrugMeloxicam - low dose
  • DrugMeloxicam - medium dose
  • DrugMeloxicam - high dose
06

What researchers measure

Primary outcomes

  1. Cmax (Maximum measured concentration of the analyte in plasma)

    Time frame: up to 96 hours after drug administration

  2. AUC0-infinity (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

    Time frame: up to 96 hours after drug administration

Secondary outcomes

  1. tmax (Time from dosing to the maximum concentration of the analyte in plasma)

    Time frame: up to 96 hours after drug administration

  2. AUC0-tf (Total area under the plasma drug concentration-time curve (AUC) from time of administration (0) to the last quantifiable drug concentration)

    Time frame: up to 96 hours after drug administration

  3. t½ (Terminal half-life of the analyte in plasma)

    Time frame: up to 96 hours after drug administration

  4. Terminal rate constant in plasma

    Time frame: up to 96 hours after drug administration

  5. CL/F (Apparent clearance of the analyte in plasma following extravascular administration)

    Time frame: up to 96 hours after drug administration

  6. Vz/F (Apparent volume of distribution of the analyte during the terminal phase)

    Time frame: up to 96 hours after drug administration

  7. MRTtot (Total mean residence time)

    Time frame: up to 96 hours after drug administration

  8. Number of patients with adverse events

    Time frame: up to 10 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2001 and a primary completion of Sep 2001. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2014
First posted
Jul 3, 2014
Start
Jun 2001
Primary completionActual
Sep 2001
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02181322
Responsible party
Sponsor
First posted
Jul 3, 2014
Start date
Jun 2001
Primary completion
Sep 2001
Last update
Jul 8, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion